1-ethyl-3-(5-(2-isopropoxyphenyl)-1H-benzo[d]imidazol-2-yl)urea | 1430719-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-ethyl-3-(5-(2-isopropoxyphenyl)-1H-benzo[d]imidazol-2-yl)urea
• 英文别名: 1-ethyl-3-[6-(2-propan-2-yloxyphenyl)-1H-benzimidazol-2-yl]urea
• CAS: 1430719-82-6
• 化学式: C₁₉H₂₂N₄O₂
• 分子量: 338.409
• InChiKey: WQTQFCFZCPXAEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  79
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-异丙氧基苯硼酸 、 4-溴邻苯二胺 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.5h， 生成 1-ethyl-3-(5-(2-isopropoxyphenyl)-1H-benzo[d]imidazol-2-yl)urea
  参考文献：
  名称：

  Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant

  摘要：

  The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.

  DOI：

  10.1021/jm301891t